성감염증 검사 시장 규모, 점유율, 성장률, 세계 산업 분석 : 유형별, 용도별, 지역별 인사이트, 예측(2026-2034년)

Growth Factors of sexually transmitted diseases (STD) testing Market

The global sexually transmitted diseases (STD) testing market is witnessing strong growth due to rising infection rates, increasing awareness of sexual health, and expanding government-led screening initiatives. According to Fortunes Business Insights, the market was valued at USD 11.07 billion in 2025 and is projected to grow from USD 11.97 billion in 2026 to USD 23.95 billion by 2034, registering a CAGR of 9.10% during the forecast period (2026-2034).

North America dominated the global market in 2025, accounting for 42.80% market share, supported by robust healthcare infrastructure, public-private partnerships, and strong government initiatives to enhance disease detection.

Market Dynamics

Rising Incidence of STDs Driving Market Growth

Sexually transmitted diseases are caused by bacteria, viruses, or parasites and are transmitted through sexual contact or vertically from mother to child. Many STDs are asymptomatic, making timely and accurate diagnosis critical to limit further transmission.

According to global estimates:

• 38.4 million people were living with HIV in 2021
• 491 million people aged 15-49 had HSV-2 infection worldwide
• High incidence rates of chlamydia, gonorrhea, syphilis, and HIV continue to increase demand for testing kits and diagnostic instruments

Increasing risky sexual behavior, lack of consistent condom usage, and limited sexual health education in certain populations are further contributing to the growing disease burden.

Market Trends

Shift from Laboratory Testing to Point-of-Care Testing

One of the most notable trends in the STD testing market is the gradual shift from laboratory-based testing to point-of-care testing (POCT). While laboratory testing dominated the market in 2026 with a share of 78.33%, POCT is expected to grow at the highest CAGR during the forecast period.

Point-of-care tests offer:

• Faster turnaround time
• Lower testing costs
• Improved accessibility
• Reduced stigma and confidentiality concerns

These benefits are encouraging healthcare providers and patients to adopt POCT solutions across hospitals, clinics, pharmacies, and homecare settings.

Segmentation Analysis

By Product Type

• Reagents & kits dominated the market in 2026, holding 79.32% share, driven by high testing volumes and recurring demand.
• Instruments are expected to grow steadily due to rising sample throughput in diagnostic laboratories.

By Application

• Chlamydia testing led the market in 2026 with a 24.47% share, owing to its high prevalence and frequent testing requirements.
• Gonorrhea, HIV, and HPV also accounted for significant market shares.
• Syphilis and genital herpes held comparatively lower shares due to limited routine screening.

By End User

• Diagnostic centers dominated the market in 2026 with 52.34% share, supported by faster service delivery and advanced diagnostic capabilities.
• Hospitals & clinics followed, especially in emerging economies.
• Home-based testing is gaining traction due to privacy and convenience benefits.

Regional Insights

• North America: Market valued at USD 4.74 billion in 2025; strong growth driven by public-private partnerships and awareness programs.
• Europe: Growth supported by advanced diagnostic infrastructure and digital result delivery systems.
• Asia Pacific: Expected to grow at the highest CAGR, supported by government initiatives and rising awareness in countries such as Japan, China, and India.
• Latin America & Middle East & Africa: Moderate growth due to increasing government and NGO-led awareness programs.

Competitive Landscape

The global STD testing market is fragmented, with major players including:

• Abbott
• F. Hoffmann-La Roche Ltd
• bioMerieux
• Bio-Rad Laboratories
• Thermo Fisher Scientific
• BD
• Hologic, Inc.

These companies are focusing on R&D investments, strategic collaborations, and product launches to expand their global presence.

Conclusion

The global sexually transmitted diseases testing market is set for strong expansion from 2026 to 2034, driven by rising disease prevalence, growing awareness, and increasing adoption of point-of-care testing solutions. With the market expected to reach USD 23.95 billion by 2034, continued government initiatives, technological advancements, and improved accessibility to testing will play a crucial role in shaping market growth. Despite challenges such as stigma and reluctance toward testing, sustained efforts by healthcare authorities and industry players are expected to significantly strengthen STD detection and prevention worldwide.

Segmentation By Product Type, Application, Setting, End User, and Region

By Product Type * Instruments

• Reagents & Kits

By Application * Chlamydia

• Syphilis
• Genital Herpes
• Gonorrhea
• Human Immunodeficiency Virus
• Human Papillomavirus
• Others

By Setting * Laboratory Testing

• Point-of-Care

By End User * Hospital & Clinics

• Diagnostic Centers
• Others

By Region * North America (By Product Type, By Application, By Setting, By End User, By Country)

• U.S.
• Canada
• Europe (By Product Type, By Application, By Setting, By End User, By Country/Sub-Region)
  • U.K.
  • Germany
  • France
  • Italy
  • Spain
  • Scandinavia
  • Rest of Europe
• Asia Pacific (By Product Type, By Application, By Setting, By End User, By Country/Sub-Region)
  • Japan
  • China
  • India
  • Australia
  • Southeast Asia
  • Rest of Asia Pacific
• Latin America (By Product Type, By Application, By Setting, By End User, By Country/ Sub-Region)
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa (By Product Type, By Application, By Setting, By End User, By Country/Sub-Region)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Table of Content

1. Introduction

• 1.1. Research Scope
• 1.2. Market Segmentation
• 1.3. Research Methodology
• 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

• 3.1. Market Drivers
• 3.2. Market Restraints
• 3.3. Market Opportunities
• 3.4. Market Trends

4. Key Insights

• 4.1. Prevalence of Key Diseases, By Key Countries, 2025
• 4.2. Key Industry Developments
• 4.3. Overview of Regulatory Scenario, By Key Countries/Regions
• 4.4. Technological Advancements in Sexually Transmitted Diseases Testing Market
• 4.5. Impact of COVID-19 on Global Sexually Transmitted Diseases Testing Market

5. Global Sexually Transmitted Diseases Testing Market Analysis, Insights and Forecast, 2021-2034

• 5.1. Market Analysis, Insights and Forecast - By Product Type
  • 5.1.1. Instruments
  • 5.1.2. Reagents & Kits
• 5.2. Market Analysis, Insights and Forecast - By Application
  • 5.2.1. Chlamydia
  • 5.2.2. Syphilis
  • 5.2.3. Genital Herpes
  • 5.2.4. Gonorrhea
  • 5.2.5. Human Immunodeficiency Virus
  • 5.2.6. Human Papillomavirus (HPV)
  • 5.2.7. Others
• 5.3. Market Analysis, Insights and Forecast - By Setting
  • 5.3.1. Laboratory Testing
  • 5.3.2. Point-of Care (POC)
• 5.4. Market Analysis, Insights and Forecast - By End User
  • 5.4.1. Hospitals and Clinics
  • 5.4.2. Diagnostic Centers
  • 5.4.3. Others
• 5.5. Market Analysis, Insights and Forecast - By Region
  • 5.5.1. North America
  • 5.5.2. Europe
  • 5.5.3. Asia Pacific
  • 5.5.4. Latin America
  • 5.5.5. Middle East & Africa

6. North America Sexually Transmitted Diseases Testing Market Analysis, Insights and Forecast, 2021-2034

• 6.1. Market Analysis, Insights and Forecast - By Product Type
  • 6.1.1. Instruments
  • 6.1.2. Reagents & Kits
• 6.2. Market Analysis, Insights and Forecast - By Application
  • 6.2.1. Chlamydia
  • 6.2.2. Syphilis
  • 6.2.3. Genital Herpes
  • 6.2.4. Gonorrhea
  • 6.2.5. Human Immunodeficiency Virus
  • 6.2.6. Human Papillomavirus (HPV)
  • 6.2.7. Others
• 6.3. Market Analysis, Insights and Forecast - By Setting
  • 6.3.1. Laboratory Testing
  • 6.3.2. Point-of Care (POC)
• 6.4. Market Analysis, Insights and Forecast - By End User
  • 6.4.1. Hospitals and Clinics
  • 6.4.2. Diagnostic Centers
  • 6.4.3. Others
• 6.5. Market Analysis, Insights and Forecast - By Country
  • 6.5.1. U.S.
  • 6.5.2. Canada

7. Europe Sexually Transmitted Diseases Testing Market Analysis, Insights and Forecast, 2021-2034

• 7.1. Market Analysis, Insights and Forecast - By Product Type
  • 7.1.1. Instruments
  • 7.1.2. Reagents & Kits
• 7.2. Market Analysis, Insights and Forecast - By Application
  • 7.2.1. Chlamydia
  • 7.2.2. Syphilis
  • 7.2.3. Genital Herpes
  • 7.2.4. Gonorrhea
  • 7.2.5. Human Immunodeficiency Virus
  • 7.2.6. Human Papillomavirus (HPV)
  • 7.2.7. Others
• 7.3. Market Analysis, Insights and Forecast - By Setting
  • 7.3.1. Laboratory Testing
  • 7.3.2. Point-of Care (POC)
• 7.4. Market Analysis, Insights and Forecast - By End User
  • 7.4.1. Hospitals and Clinics
  • 7.4.2. Diagnostic Centers
  • 7.4.3. Others
• 7.5. Market Analysis, Insights and Forecast - By Country/ Sub-Region
  • 7.5.1. U.K
  • 7.5.2. Germany
  • 7.5.3. France
  • 7.5.4. Italy
  • 7.5.5. Spain
  • 7.5.6. Scandinavia
  • 7.5.7. Rest of Europe

8. Asia Pacific Sexually Transmitted Diseases Testing Market Analysis, Insights and Forecast, 2021-2034

• 8.1. Market Analysis, Insights and Forecast - By Product Type
  • 8.1.1. Instruments
  • 8.1.2. Reagents & Kits
• 8.2. Market Analysis, Insights and Forecast - By Application
  • 8.2.1. Chlamydia
  • 8.2.2. Syphilis
  • 8.2.3. Genital Herpes
  • 8.2.4. Gonorrhea
  • 8.2.5. Human Immunodeficiency Virus
  • 8.2.6. Human Papillomavirus (HPV)
  • 8.2.7. Others
• 8.3. Market Analysis, Insights and Forecast - By Setting
  • 8.3.1. Laboratory Testing
  • 8.3.2. Point-of Care (POC)
• 8.4. Market Analysis, Insights and Forecast - By End User
  • 8.4.1. Hospitals and Clinics
  • 8.4.2. Diagnostic Centers
  • 8.4.3. Others
• 8.5. Market Analysis, Insights and Forecast - By Country/ Sub-Region
  • 8.5.1. Japan
  • 8.5.2. China
  • 8.5.3. India
  • 8.5.4. Australia
  • 8.5.5. Southeast Asia
  • 8.5.6. Rest of Asia Pacific

9. Latin America Sexually Transmitted Diseases Testing Market Analysis, Insights and Forecast, 2021-2034

• 9.1. Market Analysis, Insights and Forecast - By Product Type
  • 9.1.1. Instruments
  • 9.1.2. Reagents & Kits
• 9.2. Market Analysis, Insights and Forecast - By Application
  • 9.2.1. Chlamydia
  • 9.2.2. Syphilis
  • 9.2.3. Genital Herpes
  • 9.2.4. Gonorrhea
  • 9.2.5. Human Immunodeficiency Virus
  • 9.2.6. Human Papillomavirus (HPV)
  • 9.2.7. Others
• 9.3. Market Analysis, Insights and Forecast - By Setting
  • 9.3.1. Laboratory Testing
  • 9.3.2. Point-of Care (POC)
• 9.4. Market Analysis, Insights and Forecast - By End User
  • 9.4.1. Hospitals and Clinics
  • 9.4.2. Diagnostic Centers
  • 9.4.3. Others
• 9.5. Market Analysis, Insights and Forecast - By Country/ Sub-Region
  • 9.5.1. Brazil
  • 9.5.2. Mexico
  • 9.5.3. Rest of Latin America

10. Middle East & Africa Sexually Transmitted Diseases Testing Market Analysis, Insights and Forecast, 2021-2034

• 10.1. Market Analysis, Insights and Forecast - By Product Type
  • 10.1.1. Instruments
  • 10.1.2. Reagents & Kits
• 10.2. Market Analysis, Insights and Forecast - By Application
  • 10.2.1. Chlamydia
  • 10.2.2. Syphilis
  • 10.2.3. Genital Herpes
  • 10.2.4. Gonorrhea
  • 10.2.5. Human Immunodeficiency Virus
  • 10.2.6. Human Papillomavirus (HPV)
  • 10.2.7. Others
• 10.3. Market Analysis, Insights and Forecast - By Setting
  • 10.3.1. Laboratory Testing
  • 10.3.2. Point-of Care (POC)
• 10.4. Market Analysis, Insights and Forecast - By End User
  • 10.4.1. Hospitals and Clinics
  • 10.4.2. Diagnostic Centers
  • 10.4.3. Others
• 10.5. Market Analysis, Insights and Forecast - By Country/ Sub-Region
  • 10.5.1. GCC
  • 10.5.2. South Africa
  • 10.5.3. Rest of Middle East & Africa

11. Competitive Analysis

• 11.1. Global Market Share Analysis (2025)
• 11.2. Company Profiles (Overview, Product, SWOT Analysis, Recent Developments, Strategies, financials (Based on Availability))
  • 11.2.1. Abbott
    • 11.2.1.1. Overview,
    • 11.2.1.2. Product,
    • 11.2.1.3. SWOT Analysis,
    • 11.2.1.4. Recent Developments,
    • 11.2.1.5. Strategies,
    • 11.2.1.6. financials (Based on Availability)
  • 11.2.2. F. Hoffmann-La Roche Ltd
    • 11.2.2.1. Overview,
    • 11.2.2.2. Product,
    • 11.2.2.3. SWOT Analysis,
    • 11.2.2.4. Recent Developments,
    • 11.2.2.5. Strategies,
    • 11.2.2.6. financials (Based on Availability)
  • 11.2.3. Becton, Dickinson and Company (BD)
    • 11.2.3.1. Overview,
    • 11.2.3.2. Product,
    • 11.2.3.3. SWOT Analysis,
    • 11.2.3.4. Recent Developments,
    • 11.2.3.5. Strategies,
    • 11.2.3.6. financials (Based on Availability)
  • 11.2.4. Hologic, Inc.
    • 11.2.4.1. Overview,
    • 11.2.4.2. Product,
    • 11.2.4.3. SWOT Analysis,
    • 11.2.4.4. Recent Developments,
    • 11.2.4.5. Strategies,
    • 11.2.4.6. financials (Based on Availability)
  • 11.2.5. Danaher Corporation
    • 11.2.5.1. Overview,
    • 11.2.5.2. Product,
    • 11.2.5.3. SWOT Analysis,
    • 11.2.5.4. Recent Developments,
    • 11.2.5.5. Strategies,
    • 11.2.5.6. financials (Based on Availability)
  • 11.2.6. Thermo Fisher Scientific Inc.
    • 11.2.6.1. Overview,
    • 11.2.6.2. Product,
    • 11.2.6.3. SWOT Analysis,
    • 11.2.6.4. Recent Developments,
    • 11.2.6.5. Strategies,
    • 11.2.6.6. financials (Based on Availability)
  • 11.2.7. bioMerieux, Inc.
    • 11.2.7.1. Overview,
    • 11.2.7.2. Product,
    • 11.2.7.3. SWOT Analysis,
    • 11.2.7.4. Recent Developments,
    • 11.2.7.5. Strategies,
    • 11.2.7.6. financials (Based on Availability)
  • 11.2.8. Bio-Rad Laboratories, Inc.
    • 11.2.8.1. Overview,
    • 11.2.8.2. Product,
    • 11.2.8.3. SWOT Analysis,
    • 11.2.8.4. Recent Developments,
    • 11.2.8.5. Strategies,
    • 11.2.8.6. financials (Based on Availability)
  • 11.2.9. DiaSorin Inc.
    • 11.2.9.1. Overview,
    • 11.2.9.2. Product,
    • 11.2.9.3. SWOT Analysis,
    • 11.2.9.4. Recent Developments,
    • 11.2.9.5. Strategies,
    • 11.2.9.6. financials (Based on Availability)